Nothing Special   »   [go: up one dir, main page]

WO2002018584A3 - Xage-1, a gene expressed in multiple cancers, and uses thereof - Google Patents

Xage-1, a gene expressed in multiple cancers, and uses thereof Download PDF

Info

Publication number
WO2002018584A3
WO2002018584A3 PCT/US2001/027258 US0127258W WO0218584A3 WO 2002018584 A3 WO2002018584 A3 WO 2002018584A3 US 0127258 W US0127258 W US 0127258W WO 0218584 A3 WO0218584 A3 WO 0218584A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
xage
cancer
provides
analogs
Prior art date
Application number
PCT/US2001/027258
Other languages
French (fr)
Other versions
WO2002018584A2 (en
Inventor
Ira H Pastan
Xiu Fen Liu
Tapan K Bera
Byungkook Lee
Kristi A Egland
Original Assignee
Us Gov Health & Human Serv
Ira H Pastan
Xiu Fen Liu
Tapan K Bera
Byungkook Lee
Kristi A Egland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Ira H Pastan, Xiu Fen Liu, Tapan K Bera, Byungkook Lee, Kristi A Egland filed Critical Us Gov Health & Human Serv
Priority to AU2001287004A priority Critical patent/AU2001287004A1/en
Priority to US10/363,233 priority patent/US20040087772A1/en
Publication of WO2002018584A2 publication Critical patent/WO2002018584A2/en
Publication of WO2002018584A3 publication Critical patent/WO2002018584A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the surprising discovery that XAGE-1 is translated as two proteins, a 9 kD protein, termed p9, and a 16.3 kD protein, termed p16. The invention further relates to the surprising discovery that XAGE-1 is expressed in a number of important human cancers, specifically: prostate cancer, lung cancer, ovarian cancer, breast cancer, glioblastoma, pancreatic cancer, T cell lymphoma, melanoma, and histocytic lymphoma. The proteins p9 and p16, immunogenic fragments thereof, analogs of these proteins, and nucleic acids encoding these proteins, fragments, or analogs, can be administered to persons with XAGE-1 expressing cancers to raise or augment an immune response to the cancer. The invention further provides nucleic acid sequences encoding the proteins, as well as expression vectors, host cells, and antibodies to the proteins. Further, the invention provides immunoconjugates that comprise an antibody to p16 or to p9, and an effector molecule, such as a label, a radioisotope, or a toxin. The invention also provides methods of inhibiting the growth of XAGE-1 expressing cells by contacting them with immunoconjugates comprising an anti- p9 or p16 antibody and a toxic moiety. Further, the invention provides kits for detecting the presence of p9 or p16 in a sample.
PCT/US2001/027258 2000-09-01 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof WO2002018584A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001287004A AU2001287004A1 (en) 2000-09-01 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof
US10/363,233 US20040087772A1 (en) 2001-08-31 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22968400P 2000-09-01 2000-09-01
US60/229,684 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002018584A2 WO2002018584A2 (en) 2002-03-07
WO2002018584A3 true WO2002018584A3 (en) 2003-01-16

Family

ID=22862271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027258 WO2002018584A2 (en) 2000-09-01 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof

Country Status (2)

Country Link
AU (1) AU2001287004A1 (en)
WO (1) WO2002018584A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572887B2 (en) 2003-04-08 2009-08-11 The United States Of America As Represented By The Department Of Health And Human Services Gene expressed in prostate cancer, methods and use thereof
WO2005058944A2 (en) * 2003-12-12 2005-06-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health & Human Services Immunogenic peptides fragments of xage-1
CN103293308B (en) * 2013-05-24 2014-11-26 尉军 Amino acid sequence for detecting tumor marker P16 antigenic epitope and application of amino acid sequence
EP3535288A1 (en) 2016-11-07 2019-09-11 Immunocore Limited Peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
EP1179589A1 (en) * 2000-08-08 2002-02-13 F. Hoffmann-La Roche Ag MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
EP1179589A1 (en) * 2000-08-08 2002-02-13 F. Hoffmann-La Roche Ag MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRINKMANN U ET AL: "Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 7, 1 April 1999 (1999-04-01), pages 1445 - 1448, XP002177257, ISSN: 0008-5472 *
DATABASE EMBL [online] 23 August 2000 (2000-08-23), LIU X ET AL: "Homo sapiens XAGE-1 mRNA, complete cds.", XP002210234, retrieved from EBI Database accession no. AF251237 *
LIU XIU FEN ET AL: "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma.", CANCER RESEARCH, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4752 - 4755, XP002210232, ISSN: 0008-5472 *
ZENDMAN ALBERT J W ET AL: "Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis.", INTERNATIONAL JOURNAL OF CANCER, vol. 97, no. 2, January 2002 (2002-01-01), pages 195 - 204, XP002210233, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
AU2001287004A1 (en) 2002-03-13
WO2002018584A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
Seymour et al. A processed multidomain Mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine respiratory cilia
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
Saito et al. Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
NO20021992L (en) Anti-prostate stem cell antigen (PSCA) antibody preparation and methods of use
WO2004024750A3 (en) Cd44-binding ligands
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
NZ595896A (en) Genetic products differentially expressed in tumors and the use thereof
BRPI0516264A (en) nucleic acid molecule, nucleotide sequence, expression cassette, expression vector, cell, methods for expressing a recombinant antibody or fragment thereof, to enhance expression of a recombinant antibody or fragment thereof, to produce a recombinant antibody or fragment thereof and an antibody preparation and for detecting an irt product in a sample, antibody and pharmaceutical composition
WO2003092630A3 (en) Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2004101756A3 (en) Ovr110 antibody compositions and methods of use
HUP0500459A2 (en) Streptococcus suis vaccines and diagnostic tests
WO2000020587A3 (en) Cancer associated antigens and uses therefor
CN105277712B (en) A kind of method for identifying the modification of lysine ε amino side chains monomethylation
WO2005097185A3 (en) Irta-5 antibodies and their uses
Temporini et al. Liquid chromatography–mass spectrometry structural characterization of neo glycoproteins aiding the rational design and synthesis of a novel glycovaccine for protection against tuberculosis
EP0554389A4 (en) Molecular clones of hiv-1 and uses thereof
WO2003033520A3 (en) Anticancer vaccine and diganostic methods and reagents
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2002018584A3 (en) Xage-1, a gene expressed in multiple cancers, and uses thereof
CN106854244A (en) A kind of nano antibody and its clinical practice for HER3
HUP0302566A2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
Jurnecka et al. Bordetella pertussis and Bordetella bronchiseptica filamentous hemagglutinins are processed at different sites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10363233

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP